2024 年 4 月 2 日 – BOULDER, CO – Watchmaker Genomics, a provider of innovative solutions for molecular analysis, announced the launch of a high-purity RNase Inhibitor that is well-suited for a wide range of applications where maintaining RNA integrity is critical, including single-cell and single-nuclei sequencing, as well as pathogen detection.
“We are pleased to bring our RNase Inhibitor to market,” said Sandra Rowe, Vice President of Marketing at Watchmaker. “We aim to be a partner for our customers and provide high-performing yet cost-effective solutions to allow for higher throughput and increased sensitivity.”
Key features of Watchmaker’s RNase Inhibitor include:
- Robust protection against RNA degradation at elevated temperatures
- High-quality performance at a competitive price point
The launch of the RNase Inhibitor complements Watchmaker’s Precision Enzymes portfolio, which includes the highly thermostable and inhibitor-tolerant StellarScript HT+ Reverse Transcriptase designed for sensitive pathogen detection assays.
关于Watchmaker Genomics
Watchmaker Genomics（沃奇酶科）运用先进的酶学技术，实现各种DNA和RNA读取、写入和编辑方面的突破性应用。该公司将蛋白质工程领域的专长与大规模酶制造技术相结合，以满足高速增长的临床基因组学应用市场对产品质量、性能和生产规模方面的严苛要求。Watchmaker 的产品线包括新一代测序、合成生物学及分子诊断应用所需的精准酶及成套试剂盒。For more news and updates, follow Watchmaker Genomics on Twitter 或 扫描下方二维码。
Media Contacts:
Jen Pavlica
Sr. Product Manager, Strategic
Watchmaker Genomics
jen.pavlica@watchmakergenomics.com
